One year before Pfizer completes shutting down its Ann Arbor, Mich., research campus, and eliminated nearly 2,100 jobs in the process, the region’s life-sciences industry doesn’t appear down for the count.
 
While the pharma giant fades into history in the region, a casualty of cost-cutting tied to the rise of generic drugs and a dearth of new profitable compunds, a parade of local therapeutics and medical device companies, as well as automotive and aerospace companies, are growing.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.